$GLSI News

HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69

Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me

Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward

Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe

Greenwich LifeSciences The Overlooked Need

Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate

Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026

Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial

Greenwich LifeSciences Receives Nasdaq Noncompliance Notice

Greenwich LifeSciences Receives Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Receives Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data

Greenwich Lifesciences Used Its ATM Facility To Issue Shares Directly Into The Market At Prevailing Prices. Proceeds Raised In Q1 2026 Exceeded The Quarter's Cash Burn, Resulting In An Estimated Cash Balance Of About $10.5M As Of March 31

Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim

Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Greenwich LifeSciences Expands Breast Cancer Trial Across Major US Cancer Centers, Launches New Study Sites To Advance Cancer Recurrence Therapy

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Greenwich LifeSciences To Present Two Posters At AACR 2026, Including First FLAMINGO-01 Statistically Significant Immune Response Data